Calcipotriol in the treatment of psoriasis of limited severity: Pharmacoeconomic evaluation

Journal of Cutaneous Medicine and Surgery

Volumn 2, Issue 1, 1997, Pages 7-15

  Oh, Paul I ^a,b   Gupta, Aditya K ^a,b   Einarson, Thomas R ^a   Maerov, Phillip ^a   Shear, Neil H ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; FLUOCINONIDE; STEROID;

ALGORITHM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECISION MAKING; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; META ANALYSIS; PHARMACOECONOMICS; PHYSICIAN; PRIORITY JOURNAL; PSORIASIS; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; TREATMENT FAILURE;

EID: 0031391433     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1177/120347549700200103     Document Type: Article

References (48)

1. Greaves M, Weinstein G. Treatment of psoriasis. N Engl J Med 1996; 332:581-588.
2. Canadian Coordinating Office for Health Technology Assessment. Guidelines for the economic evaluation of pharmaceuticals. Canada. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1994.
3. Drake L, Ceilley R, Cornelison R. Guidelines for care of psoriasis. J Am Acad Dermatol 1993; 28:632-637.
4. Kragballe K. Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol. Arch Dermatol 1989; 125:1647-1652.
5. Kragballe K. Treatment of psoriasis with calcipotriol and other vitamin D analogues. J Am Acad Dermatol 1992; 27:1001-1008.
6. Kragballe K, Fogh K, Sogaard H. Long term efficacy and tolerability of topical calcipotriol in psoriasis: results of an open study. Acta Derm Venereol (Stockh) 1991; 71:475-478.
7. Ramsay CA. Calcipotriol and psoriasis. Int J Dermatol 1992; 31:549-550.
8. 3 analogue (MC 903) in a double-blind study. Br J Dermatol 1988; 119:223-230.
9. Cunliffe WJ, Berth-Jones J, Claudy A, et al. Comparative study of calcipotriol (MC 903) ointment and beramethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992; 26:736-743.
10. Dubertret L, Wallach D, Souteyrand P, et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 1992; 27:983-988.
11. Berth-Jones J, Chu AC, Dodd WAH, et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992; 127:266-271.
12. Poyner T, Hughes IW, Dass BK, Adnitt PI. Long-term treatment of chronic plaque psoriasis with calcipotriol. J Dermatol Treat 1993; 4:173-177.
13. Menne T, Larsen K. Psoriasis treatment with vitamin D derivatives. Sem Dermatol 1992; 11:278-283.
14. Tham SN, Lun KC, Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994; 131:673-677.
15. Grossman RM, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994; 31:68-74.
16. Speight EL, Farr PM. Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol 1994; 130:79-82.
17. Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994; 130:483-487.
18. Bruce S, Epinette WW, Funicella T, et al. Comparative study of calcipotriol (MC 903) ointment and fluocinonide ointment in treatment of psoriasis. J Am Acad Dermatol 1994; 31:755-759.
19. Drug Benefit Formulary. Comparative Drug Index. Ontario Ministry of Health, Toronto, 1994.
20. Schedule of Benefits. Physician services under the Health Insurance Act. Ontario Ministry of Health, Toronto, 1992.
21. Sander HM, Morris LF, Phillips CM, et al. The annual cost of psoriasis. J Am Acad Dermatol 1993; 28:422-425.
22. Drummond MF, Stoddart GL, Torrance GW. Cost-utility analysis. In: Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1993:112-148.
23. Laupacis A, Feeny D, Detsky A, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146:473-480.
24. Ramsay CA, Berth-Jones J, Brundin G, et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994; 189:260-264.
25. Mortensen L. Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effects on calcium or bone metabolism. Acta Derm Venereol (Stockh) 1993; 73:300-304.
26. Charney P. Betamethasone dipropionate cream for the treatment of psoriasis. Arch Dermatol 1976; 112:681-683.
27. Mensing H, Korsukewitz G, Yawalkar S. A double-blind, multicenter comparison between halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis. J Am Acad Dermatol 1991; 25:1149-1152.
28. Katz HI, Hien JT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris - clinical efficacy and adrenal function. Treatment with either betamethasone dipropionate in optimized vehicle or clobetasol-17. J Am Acad Dermatol 1987; 16:804-811.
29. Huntley AC, Isseroff R. Amcinonide vs. betamethasone dipropionate ointments in the treatment of psoriasis. Cutis 1985; 35:489-492.
30. Shupack JL, Jondreau L, Kenny C, Stiller MJ. Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis. Dermatology 1993; 186:129-132.
31. Mali JWH. An evaluation of betamethasone dipropionate (Diprosone) versus Locacorten 0.02% cream. Dermatologica 1976; 153:177-178.
32. Vanderploeg DE. Betamethasone dipropionate ointment in the treatment of psoriasis and atopic dermatitis: a double-blind study. South J Med 1976; 69:862-863.
33. English JSC, Bunker CB, Ruthven K, et al. A double-blind comparison of the efficacy of betamethasone dipropionate cream twice daily versus once daily in the treatment of steroid-responsive dermatoses. Clin Exp Dermatol 1989; 14:32-34.
34. Christiansen JV, Holm P, Moller R, et al. Etretinate (Tigason) and betamethasone valerate (Celeston valerate) in the treatment of psoriasis. A double-blind, randomized, multicenter trial. Dermatologica 1982; 165:204-207.
35. Barsky S. Multicenter trial analysis. Fluocinonide and betamethasone gel in psoriasis. Arch Dermatol 1976; 112:1729-1733.
36. Blum G, Yawalkar S. A comparative, multicenter, double-blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol 1991; 25:1153-1156.
37. Christiansen JV, Foged E, Holm P, et al. The treatment of psoriasis with 0.1% domoprednate (a D-homocorticosteroid) and 0.1% betamethasone valerate ointment. A double-blind, randomized trial. Dermatologica 1985; 170:195-198.
38. Wilkinson RD, Ohayon M. Therapeutic response to a dermatologic patch and betamethasone valerate 0.1 percent cream in the management of chronic plaques in psoriasis. Cutis 1990; 45:468-470.
39. Kragballe K. Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903). Arch Dermatol 1989; 125:1647-1652.
40. Kragballe K, Fogh K, Sogaard M. Long term efficacy and tolerability of topical calcipotriol in psoriasis. Acta Derm Venereol (Stockh) 1991; 71:475-478..
41. Comparative effects of calcipotriol (50 mg/g) (Dovonex ointment) and 5% coal tar/2% allantoin/0.5% hydrocortisone cream (Alphosyl HC cream) in the treatment of psoriasis vulgaris. Data on file. United Kingdom: Leo Laboratories, 1993.
42. Scarpa C. Calcipotriol: clinical trial versus betamethasone dipropionate + salicylic acid. Acta Derm Venereol (Stockh) 1994; Suppl 186:47.
43. Goldberg B, Hartdegen R, Presbury D, et al. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol 1991; 25:1145-1148.
44. Engel MF. Treatment of psoriasis with amcinonide 0.1 percent and fluocinonide 0.05 percent ointments. A comparative double-blind study. Cutis 1982; 29:646-649.
45. Savin RC, Stoughton RB, Cornell RC, et al. Comparative study of desoximetasone ointment 0.25% versus fluocinonide ointment 0.05% in patients with psoriasis. Clin Ther 1985; 8:118-125.
46. Close JE. Double-blind comparison of topical halcinonide and fluocinonide in the treatment of psoriasis. Int J Dermatol 1976; 15:534-537.
47. Katz HI, Prawer SE, Medansky RS, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991; 183: 269-274.
48. Larko O, Swanbeck G, Svartholm H. The effect on psoriasis of clobetasol propionate used alone or in combination with UVB. Acta Derm Venereol (Stockh) 1984; 64:151-154.